<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115112</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-423</org_study_id>
    <nct_id>NCT03115112</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effects of Bexagliflozin Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of bexagliflozin compared to&#xD;
      sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in&#xD;
      subjects with type 2 diabetes mellitus (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase 3, multi-center, randomized, double-blind, parallel-group study to&#xD;
      demonstrate that bexagliflozin was non-inferior to sitagliptin as add-on therapy in subjects&#xD;
      whose T2DM was not adequately controlled by metformin treatment alone. The primary&#xD;
      effectiveness endpoint was the change in HbA1c from baseline at week 24.&#xD;
&#xD;
      At the time of screening, all subjects were to have taken metformin at a stable dose of ≥&#xD;
      1500 mg per day for ≥ 8 weeks and have received diet and exercise counseling. A total of 374&#xD;
      eligible subjects were to be enrolled in the study. Subjects who successfully completed a&#xD;
      1-week run-in and who met all eligibility criteria were to be randomized in a 1:1 ratio to&#xD;
      receive once daily double-blind treatment of either active bexagliflozin tablets with placebo&#xD;
      sitagliptin tablets or placebo bexagliflozin tablets and active sitagliptin tablets. The&#xD;
      study subjects were to continue receiving open-labeled metformin during the entire study at a&#xD;
      stable dose and frequency. The treatment period was 24 weeks and was conducted in an&#xD;
      outpatient setting.&#xD;
&#xD;
      Randomization was stratified by HbA1c (≤ 8.5% vs. ˃ 8.5%) values. Symptoms and blood sugars&#xD;
      related to the occurrence of hyperglycemia, hypoglycemic events or symptoms that could&#xD;
      indicate ketoacidosis were to be recorded. Bexagliflozin tablets, 20 mg or placebo, and&#xD;
      sitagliptin tablets, 100 mg or placebo, were to be taken once daily at approximately the same&#xD;
      time each day either before or after breakfast. Background metformin was to be taken at the&#xD;
      same dose and frequency from screening throughout the entire study.&#xD;
&#xD;
      Each subject was advised to return to the clinic at weeks 6, 12, 18 and 24 for efficacy&#xD;
      assessment and safety monitoring, including review of AEs and concomitant medication, vital&#xD;
      signs, ECG, physical examination and blood and urine specimen collections. Subjects were to&#xD;
      return to the clinic for a follow-up exit visit at week 26 or 2 weeks after the last dose of&#xD;
      study drugs if subjects withdrew from the study prior to week 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c From Baseline to Week 24</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>The primary efficacy objective is to demonstrate that bexagliflozin is non-inferior to sitagliptin by evaluating the treatment effect on hemoglobin A1c (HbA1c) reduction at week 24 in subjects whose type 2 diabetes mellitus (T2DM) is inadequately controlled by metformin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FPG From Baseline at Week 24</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in fasting plasma glucose (FPG) at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight in Subjects With Baseline BMI ≥ 25 kg/m2 at Week 24</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in body weight in subjects with baseline body mass index (BMI) ≥ 25 kg/m2 at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SBP in Subjects From Baseline at Week 24</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in systolic blood pressure (SBP) in subjects at week 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">386</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Bexagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>tablets containing 20 mg bexagliflozin</description>
    <arm_group_label>Bexagliflozin</arm_group_label>
    <other_name>EGT0001442, EGT0001474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>tablets containing 100 mg sitagliptin</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for sitagliptin</intervention_name>
    <description>inactive tablets to match the appearance of sitagliptin tablets</description>
    <arm_group_label>Bexagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for bexagliflozin</intervention_name>
    <description>inactive tablets to match the appearance of bexagliflozin tablets</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Each subject was required to meet the following criteria at the time of enrollment to be&#xD;
        eligible for the study:&#xD;
&#xD;
          1. To have been male or female adults ≥ 18 years of age.&#xD;
&#xD;
          2. To have been negative on the urine pregnancy test and agreed to abstain from coitus or&#xD;
             use contraception during the entire study if a subject was female of childbearing&#xD;
             potential.&#xD;
&#xD;
          3. To have had a diagnosis of T2DM with HbA1c levels between 7.0% and 11% (inclusive) at&#xD;
             the time of screening.&#xD;
&#xD;
          4. To have been treated with a stable dose of ≥ 1500 mg/day metformin only along with&#xD;
             diet and exercise counseling for at least 8 weeks at the time of screening.&#xD;
&#xD;
          5. To have had a BMI ≤ 45 kg per m2 at the time of screening.&#xD;
&#xD;
          6. To have been taking stable doses of treatment for dyslipidemia and/or hypertension for&#xD;
             30 days if applicable.&#xD;
&#xD;
          7. To have been willing and able to return for all clinic visits and to complete all&#xD;
             study-required procedures.&#xD;
&#xD;
          8. To have adhered to the investigational product administration requirements as&#xD;
             evidenced by missing no more than 1 day of run-in medications.&#xD;
&#xD;
        Potential subjects who exhibited any of the following characteristics were to be excluded&#xD;
        from the study:&#xD;
&#xD;
          1. Diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young (MODY)&#xD;
&#xD;
          2. Hemoglobinopathy that affected HbA1c measurement&#xD;
&#xD;
          3. Any contraindication to the safe use of DPP-4 therapy or sitagliptin, including known&#xD;
             hypersensitivity reaction&#xD;
&#xD;
          4. History of pancreatitis&#xD;
&#xD;
          5. Genitourinary tract infection within 6 weeks of screening or history of ≥ 3&#xD;
             genitourinary infections requiring treatment within 6 months from the time of&#xD;
             screening&#xD;
&#xD;
          6. Cancer, active or in remission, for &lt; 3 years&#xD;
&#xD;
          7. History of alcohol or illicit drug abuse in the past 2 years&#xD;
&#xD;
          8. Triglycerides &gt; 500 mg dL-1 at Visit V1&#xD;
&#xD;
          9. Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase &gt;&#xD;
             1.5 x upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome);&#xD;
             or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.5 x ULN&#xD;
&#xD;
         10. Estimated GFR, as calculated by the modification of diet in renal disease study&#xD;
             equation (MDRD), &lt; 60 mL min-1 per 1.73 m2 at the time of screening.&#xD;
&#xD;
         11. Uncontrolled hypertension (SBP &gt; 160 mm Hg or diastolic BP &gt; 95 mm Hg) at Visit V1&#xD;
&#xD;
         12. Life expectancy &lt; 2 years&#xD;
&#xD;
         13. History of MI, unstable angina, stroke or hospitalization for heart failure within 3&#xD;
             months at the time of screening&#xD;
&#xD;
         14. History of treatment with an investigational drug within 30 days or within 7&#xD;
             half-lives of the investigational drug, whichever is longer&#xD;
&#xD;
         15. Previous treatment with bexagliflozin or EGT0001474 study drug&#xD;
&#xD;
         16. Currently or within 3 months of taking any SGLT2 inhibitor&#xD;
&#xD;
         17. Currently participating in another interventional trial&#xD;
&#xD;
         18. Prior renal transplantation or evidence of nephrotic syndrome (defined as a urine&#xD;
             albumin-to-creatinine ratio (UACR) &gt; 1500 mg g-1 at the time of screening).&#xD;
&#xD;
         19. Any condition, disease, disorder or clinically relevant abnormality that could have&#xD;
             jeopardized the subject's appropriate participation in this study or obscure the&#xD;
             effects of treatment&#xD;
&#xD;
         20. Female subjects who were pregnant or nursing&#xD;
&#xD;
         21. Two or more consecutive SMBG measures ≥ 250 mg dL-1 (13.9 mmol L-1) prior to&#xD;
             randomization accompanied by clinical signs or symptoms of hyperglycemia prior to&#xD;
             randomization, including weight loss, blurred vision, increased thirst increased&#xD;
             urination, or fatigue&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Paul Lock, MD</last_name>
    <role>Study Director</role>
    <affiliation>Theracos Sub, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Site 1357</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 1358</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 1361</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 1031</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 1271</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 1359</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 1009</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 1037</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 1008</name>
      <address>
        <city>Munroe Falls</city>
        <state>Ohio</state>
        <zip>44262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 1360</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 3119</name>
      <address>
        <city>Hodonín</city>
        <zip>695 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 3123</name>
      <address>
        <city>Mladá Boleslav</city>
        <zip>293 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 3120</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 3112</name>
      <address>
        <city>Praha</city>
        <zip>181 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 3122</name>
      <address>
        <city>Prostějov</city>
        <zip>796 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9102</name>
      <address>
        <city>Balatonfüred</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9101</name>
      <address>
        <city>Balatongyörök</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9106</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9107</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9105</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9103</name>
      <address>
        <city>Zamardi</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6031</name>
      <address>
        <city>Chiba</city>
        <zip>260-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6037</name>
      <address>
        <city>Chiba</city>
        <zip>272-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6042</name>
      <address>
        <city>Chiba</city>
        <zip>277-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6040</name>
      <address>
        <city>Fukuoka</city>
        <zip>819-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6035</name>
      <address>
        <city>Fukuoka</city>
        <zip>819-0168</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6034</name>
      <address>
        <city>Ibaraki</city>
        <zip>300-0835</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6039</name>
      <address>
        <city>Ibaraki</city>
        <zip>300-1207</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6041</name>
      <address>
        <city>Ibaraki</city>
        <zip>306-0232</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6032</name>
      <address>
        <city>Ibaraki</city>
        <zip>310-0826</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6036</name>
      <address>
        <city>Shizuoka</city>
        <zip>424-0855</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6038</name>
      <address>
        <city>Tochigi</city>
        <zip>323-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 6033</name>
      <address>
        <city>Ōsaka</city>
        <zip>582-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7137</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-858</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7144</name>
      <address>
        <city>Kraków</city>
        <zip>30-015</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7142</name>
      <address>
        <city>Kraków</city>
        <zip>31-209</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7139</name>
      <address>
        <city>Kraków</city>
        <zip>31-261</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7141</name>
      <address>
        <city>Kraków</city>
        <zip>31-530</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7120</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7138</name>
      <address>
        <city>Lublin</city>
        <zip>20-538</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7131</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-117</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7143</name>
      <address>
        <city>Poznań</city>
        <zip>60-819</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7140</name>
      <address>
        <city>Poznań</city>
        <zip>60-821</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7136</name>
      <address>
        <city>Poznań</city>
        <zip>61-655</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7107</name>
      <address>
        <city>Puławy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 7128</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9002</name>
      <address>
        <city>Alicante</city>
        <zip>03004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9016</name>
      <address>
        <city>Almería</city>
        <zip>04001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9005</name>
      <address>
        <city>Alzira</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9017</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9013</name>
      <address>
        <city>Barcelona</city>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9012</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9011</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9014</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9015</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 9018</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>May 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2021</results_first_posted>
  <disposition_first_submitted>December 18, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>December 18, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 19, 2018</disposition_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Bexagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03115112/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03115112/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bexagliflozin</title>
          <description>Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet&#xD;
Placebo for sitagliptin: 100 mg inactive tablet to match active comparator</description>
        </group>
        <group group_id="P2">
          <title>Sitagliptin</title>
          <description>Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.&#xD;
Sitagliptin: 100 mg, tablet&#xD;
Placebo for bexagliflozin: 20 mg inactive tablet to match active comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention-to-treat</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bexagliflozin</title>
          <description>Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.</description>
        </group>
        <group group_id="B2">
          <title>Sitagliptin</title>
          <description>Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="191"/>
            <count group_id="B2" value="193"/>
            <count group_id="B3" value="384"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.3" spread="9.69"/>
                    <measurement group_id="B2" value="59.6" spread="9.76"/>
                    <measurement group_id="B3" value="59.4" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="374"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.4" spread="10.67"/>
                    <measurement group_id="B2" value="168.3" spread="9.63"/>
                    <measurement group_id="B3" value="167.9" spread="10.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.27" spread="20.736"/>
                    <measurement group_id="B2" value="89.44" spread="19.235"/>
                    <measurement group_id="B3" value="89.85" spread="19.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.06" spread="6.052"/>
                    <measurement group_id="B2" value="31.39" spread="5.294"/>
                    <measurement group_id="B3" value="31.72" spread="5.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.94" spread="0.808"/>
                    <measurement group_id="B2" value="8.03" spread="0.921"/>
                    <measurement group_id="B3" value="7.99" spread="0.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c From Baseline to Week 24</title>
        <description>The primary efficacy objective is to demonstrate that bexagliflozin is non-inferior to sitagliptin by evaluating the treatment effect on hemoglobin A1c (HbA1c) reduction at week 24 in subjects whose type 2 diabetes mellitus (T2DM) is inadequately controlled by metformin.</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>Subjects in the intention-to-treat population and with a value at baseline and at week 24 were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin</title>
            <description>Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet&#xD;
Placebo for sitagliptin: 100 mg inactive tablet to match active comparator</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.&#xD;
Sitagliptin: 100 mg, tablet&#xD;
Placebo for bexagliflozin: 20 mg inactive tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline to Week 24</title>
          <description>The primary efficacy objective is to demonstrate that bexagliflozin is non-inferior to sitagliptin by evaluating the treatment effect on hemoglobin A1c (HbA1c) reduction at week 24 in subjects whose type 2 diabetes mellitus (T2DM) is inadequately controlled by metformin.</description>
          <population>Subjects in the intention-to-treat population and with a value at baseline and at week 24 were included.</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" lower_limit="-0.86" upper_limit="-0.62"/>
                    <measurement group_id="O2" value="-0.82" lower_limit="-0.93" upper_limit="-0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin of 0.35% was determined based on a reference clinical trial that demonstrated the effectiveness of sitagliptin, 100 mg, compared to placebo on HbA1c reduction in subjects with type 2 DM. A margin of 0.35% was selected to be approximately half of sitagliptin effect and remained clinically meaningful.</non_inferiority_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>Mixed-effects repeated measures analysis includes region, treatment, visit, treatment-by-visit interaction and the baseline HbA1c value as fixed effect covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FPG From Baseline at Week 24</title>
        <description>To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in fasting plasma glucose (FPG) at week 24</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>Subjects in the intention-to-treat population and with values at baseline and at week 24 were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin</title>
            <description>Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet&#xD;
Placebo for sitagliptin: 100 mg inactive tablet to match active comparator</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.&#xD;
Sitagliptin: 100 mg, tablet&#xD;
Placebo for bexagliflozin: 20 mg inactive tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FPG From Baseline at Week 24</title>
          <description>To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in fasting plasma glucose (FPG) at week 24</description>
          <population>Subjects in the intention-to-treat population and with values at baseline and at week 24 were included.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" lower_limit="-2.09" upper_limit="-1.55"/>
                    <measurement group_id="O2" value="-1.45" lower_limit="-1.70" upper_limit="-1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0123</p_value>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Covariate includes region, treatment, visit, treatment-by-visit interaction and the baseline FPG value as a fixed effect covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight in Subjects With Baseline BMI ≥ 25 kg/m2 at Week 24</title>
        <description>To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in body weight in subjects with baseline body mass index (BMI) ≥ 25 kg/m2 at week 24</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>Subjects in the intention-to-treat population with a baseline body mass index &gt;= 25 kg/m2 and had body weight values at baseline and at week 24 were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin</title>
            <description>Subjects received a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects continued taking metformin and received placebo for sitagliptin daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet&#xD;
Placebo for sitagliptin: 100 mg inactive tablet to match active comparator</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Subjects received a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects continued taking metformin and received placebo for bexagliflozin for the duration of the study.&#xD;
Sitagliptin: 100 mg, tablet&#xD;
Placebo for bexagliflozin: 20 mg inactive tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight in Subjects With Baseline BMI ≥ 25 kg/m2 at Week 24</title>
          <description>To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in body weight in subjects with baseline body mass index (BMI) ≥ 25 kg/m2 at week 24</description>
          <population>Subjects in the intention-to-treat population with a baseline body mass index &gt;= 25 kg/m2 and had body weight values at baseline and at week 24 were included in the analysis.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.35" lower_limit="-3.85" upper_limit="-2.84"/>
                    <measurement group_id="O2" value="-0.81" lower_limit="-1.29" upper_limit="-0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed-effects repeated measures</method>
            <method_desc>Included region, treatment, visit, treatment-by-visit interaction and the baseline body weight value as fixed effect covariate.</method_desc>
            <param_type>Difference of LS Means</param_type>
            <param_value>-2.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.15</ci_lower_limit>
            <ci_upper_limit>-1.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SBP in Subjects From Baseline at Week 24</title>
        <description>To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in systolic blood pressure (SBP) in subjects at week 24</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>Subjects in the intention-to-treat population with values at baseline and at week 24 were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Bexagliflozin</title>
            <description>Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.&#xD;
Bexagliflozin: 20 mg, tablet&#xD;
Placebo for sitagliptin: 100 mg inactive tablet to match active comparator</description>
          </group>
          <group group_id="O2">
            <title>Sitagliptin</title>
            <description>Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.&#xD;
Sitagliptin: 100 mg, tablet&#xD;
Placebo for bexagliflozin: 20 mg inactive tablet to match active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SBP in Subjects From Baseline at Week 24</title>
          <description>To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in systolic blood pressure (SBP) in subjects at week 24</description>
          <population>Subjects in the intention-to-treat population with values at baseline and at week 24 were included.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.23" lower_limit="-6.18" upper_limit="-2.28"/>
                    <measurement group_id="O2" value="-1.90" lower_limit="-3.75" upper_limit="-0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0276</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>p value was presented based on one sided statistical tests using a 0.025 level of significance</method_desc>
            <param_type>mixed-effects repeated measures</param_type>
            <param_value>-2.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.70</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
            <estimate_desc>Included region, treatment, visit, treatment-by-visit interaction and the baseline body weight value as fixed effect covariate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from 1 week prior to randomization (V2) until Week 26 (V8/follow up visit)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bexagliflozin</title>
          <description>Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.</description>
        </group>
        <group group_id="E2">
          <title>Sitagliptin</title>
          <description>Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gallstone ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial aneursym</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="191"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="191"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator has no right to publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Albert Collinson</name_or_title>
      <organization>Theracos Sub, LLC</organization>
      <phone>(508) 630-2129</phone>
      <email>acollinson@theracos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

